Начало › Глиобластом › Калифорния › Los Angeles
Клинични проучвания за Глиобластом в Los Angeles, CA
24 проучвания за Глиобластом търсят участници в обекти в и около Los Angeles (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
Набиране на участнициФаза 3
- Kaiser Permanente, Los Angeles
- UCLA, Los Angeles
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
Набиране на участнициФаза 3
- Keck Medicine of USC, Los Angeles
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Набиране на участнициФаза 1/2
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Набиране на участнициФаза 2/3
- Cedars Sinai - Samuel Oschin Comprehensive Cancer Institute, Los Angeles
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Набиране на участнициФаза 2
- Cedars-Sinai Medical Center, Los Angeles
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Набиране на участнициФаза 1/2
- Children's Hospital Los Angeles, Los Angeles
- University of California at Los Angeles, Los Angeles
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Набиране на участнициФаза 1/2
- University of Southern California, Los Angeles
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
Набиране на участнициФаза 1/2
- Cedars-Sinai Medical Center, Los Angeles
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
Набиране на участнициФаза 1
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
Набиране на участнициФаза 3
- USC / Norris Comprehensive Cancer Center, Los Angeles
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Набиране на участнициФаза 1/2
- UCLA Health Bowyer Oncology Center, Los Angeles
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Набиране на участнициФаза 1
- University of California, Los Angeles (Data Collection Only), Los Angeles
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Набиране на участнициФаза 3
- University of California, Los Angeles, Los Angeles
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
Набиране на участнициФаза 2
- Cedars-Sinai Medical Center, Los Angeles
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
Набиране на участнициФаза 2
- Cedars-Sinai Medical Center, Los Angeles
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Набиране на участнициФаза 1
- University of California, Los Angeles (UCLA) Department of Medicine - Hematology/Oncology, Los Angeles
PH Sensitive MRI Based Resections of Glioblastoma
Набиране на участнициФаза 1
- Ronald Reagan Medical Center, Los Angeles
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Набиране на участници
- Oncology Institute for Hope and Innovation, Los Angeles
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Набиране на участнициФаза 1/2
- University of California Los Angeles, Los Angeles
Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients
Набиране на участнициФаза 3
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma
Набиране на участници
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
Набиране на участнициФаза 1/2
- University of California at Los Angeles, Los Angeles
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Набиране на участнициФаза 1/2
- Cedars Sinai Medical Center, Los Angeles
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Набиране на участнициФаза 2
- Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute, Los Angeles
Проучвания за Глиобластом в други градове
- New York City, NY30 проучвания
- Boston, MA28 проучвания
- Houston, TX26 проучвания
- Durham, NC20 проучвания
- San Francisco, CA17 проучвания
- Chicago, IL15 проучвания
- Washington, DC15 проучвания
- Columbus, OH14 проучвания
- Miami, FL14 проучвания
- Rochester, MN13 проучвания
- Jacksonville, FL13 проучвания
- Aurora, CO12 проучвания
Други проучвания в Los Angeles
- Рак на белия дроб с недребноклетъчен тип87 проучвания
- Рак (всички видове)74 проучвания
- Рак на гърдата73 проучвания
- Рак на простатата61 проучвания
- Колоректален рак59 проучвания
- Метастатичен рак57 проучвания
- Рак на яйчниците50 проучвания
- Рак на белия дроб45 проучвания
- Плоскоклетъчен карцином на главата и шията42 проучвания
- Рак на панкреаса35 проучвания
- Ендометриален рак34 проучвания
- Меланом34 проучвания
От ClinicalTrials.gov, данни към 6.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.